

FOR IMMEDIATE RELEASE  
Website: <http://www.arthrt.com>

Contact: David A. Garrison  
(978) 345-5000

25 Sawyer Passway  
Fitchburg, MA 01420  
P. 978 345 5000  
F. 978 342 0168

February 8, 2010

[www.arthrt.com](http://www.arthrt.com)

## ARRHYTHMIA RESEARCH TECHNOLOGY, INC. ANNOUNCES OEM VERSION OF PREDICTOR™ SAECG SOFTWARE

Fitchburg, MA

Arrhythmia Research Technology, Inc. (the “Company”) (NYSE AMEX: HRT) is pleased to announce it successfully converted its proprietary signal-averaged electrocardiography (SAECG) software PREDICTOR™ that has run on a single hardware based platform, ART 1200-EPX, to a customizable modular software product that is reconfigurable for a variety of hardware platforms. The conversion allows PREDICTOR™ to be used with customer-specific electrocardiogram acquisition equipment to generate the signal-averaged ECG. The software can be easily customized to interface with a variety of Original Equipment Manufacturer (“OEM”) hardware. OEM customers can license PREDICTOR™ and bundle it with other cardiac diagnostic software packages incorporated in their acquisition equipment.

James E. Rouse, the Company’s President and CEO commented, “We are very pleased to announce the availability of the PREDICTOR™ SAECG analysis software to the OEM market. The patented methodology used in PREDICTOR™ is considered by the American College of Cardiology and the American Heart Association to be the “Gold Standard” in signal-averaged electrocardiography analysis. It is a very valuable risk stratification tool for electrophysiologists and cardiologists in the management of post myocardial infarction patients. PREDICTOR™ is currently being used in a National Institutes for Health (“NIH”) funded investigation into “Risk Stratification in MADIT II Type Patients”. According to the Principal Investigator for the NIH study, Wojciech Zareba, MD, PhD, of the University of Rochester, “It is likely that SAECG and Microvolt T-Wave Alternans tests will emerge as routine for identifying low-risk and high-risk patients considered for ICD therapy.” Results from this study are expected to be forthcoming in late 2011.”

A signal-averaged electrocardiogram detects cardiac microvolt signals. Signal averaging, which improves the signal to noise ratio, is a well-recognized technique for detecting and analyzing such cardiac microvolt signals. High resolution acquisition equipment is used to collect the microvolt signals and transfer the data to an analytical system. ART’s patented PREDICTOR™ software embedded in the system then filters and analyzes the data to present the signal-averaged ECG for interpretation by a cardiologist.

For more information about PREDICTOR™ software, please visit:

<http://www.arthrt.com/products/predictor>

### About Arrhythmia Research Technology, Inc.

The Company’s products include proprietary signal-averaging electrocardiography (SAECG) software used in the detection of potentially lethal heart arrhythmias. The Company through its wholly owned subsidiary Micron Products, Inc. manufactures silver plated and non-silver plated conductive resin sensors and distributes metal snaps used in the manufacture of disposable ECG, EEG, EMS and TENS electrodes. Micron’s MIT division provides end-to-end product life cycle management through a comprehensive portfolio of value-added services such as design, engineering, prototyping, manufacturing, machining, assembly and packaging. MIT manufactures custom injection molded products for medical, electronic, industrial and consumer applications, and provides high end mold design, manufacturing and precision machining for various industries.

For more information please visit our websites:

<http://www.arthrt.com>

<http://www.micronproducts.com>

<http://www.micronintegrated.com>